In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.

Studies featured in this episode include:

• AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003)
• CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341)
• Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048)
• BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001)
• 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341)
• JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005)

Click here to read more and watch the full video at RheumatologyLive.